ArticleMedComm2026
Efficacy and Safety of Fruquintinib Plus TAS-102 in Patients With Previously Treated Metastatic Colorectal Cancer: Results From a Single-Arm, Multi-Center, Phase II Study.
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical efficacy of currently available third- and later-line treatment regimens for patients with metastatic colorectal cancer (mCRC) remains suboptimal. This study was designed to investigate fruquintinib plus TAS-102 regimen in this patient population. This study was a prospective, multi-center, single-arm phase II trial. A total of 50 patients with mCRC who had experienced treatment failure to at least two standard therapies were enrolled. The primary endpoint was progression-free survival (PFS) and secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety. Survival outcomes were estimated using the Kaplan-Meier method. With a median follow-up duration of 25.1 months, the median PFS was 6.07 months (95% CI: 4.07-7.87) and the median OS was 14.10 months (95% CI: 9.84-23.28). The ORR was 10.0% (95% CI: 3.3-21.8), with a DCR of 66.0% (95% CI: 51.2-78.8). All the patients experienced treatment-related adverse events (TRAEs), with 68.0% reporting grade ≥ 3 TRAEs. No serious adverse events (AEs), deaths, or new safety concerns were reported. In conclusion, fruquintinib combined with TAS-102 showed preliminary anti-tumor activity with a manageable safety profile in patients with refractory mCRC, which highlights its potential as a viable later-line therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.